An implantable loop recorder, or ILR, is a small heart-monitoring device placed just under the skin of the chest that continuously records your heart’s electrical activity for years at a time. About the size of a USB flash drive, it sits in a shallow pocket of tissue and silently watches for irregular rhythms that shorter monitoring methods tend to miss. ILRs have become one of the most useful tools in cardiology for catching heart-rhythm problems that come and go unpredictably, and the technology has changed considerably in the past decade.
What an ILR Actually Does
The device works like a single-lead ECG that never turns off. It picks up the electrical signals of each heartbeat through two electrodes on the device itself, logging the data in its internal memory. When it detects something abnormal, like a heart rate that is too fast, too slow, or irregularly irregular, it automatically stores that segment. You also get a handheld activator (or a smartphone app, depending on the model) so you can manually trigger a recording if you feel symptoms like dizziness or palpitations. The stored recordings are then transmitted wirelessly to your medical team, usually on a daily basis through a bedside monitor or phone-based system.
Modern ILRs download key data automatically each day to a web-based system where a nurse or technician reviews the recordings, typically every working day. If something concerning shows up, the clinical team contacts you directly. Additional manual transmissions can be sent by the patient when symptoms occur or when the doctor requests one.
How the Implant Procedure Works
Getting an ILR placed is a minor procedure, usually done under local anesthesia in an outpatient setting or electrophysiology lab. The doctor makes a small incision, typically over the left side of the chest near the breastbone, and slides the device into a shallow pocket just beneath the skin. The whole thing takes about ten minutes. You go home the same day, often with nothing more than a small adhesive strip over the insertion site.
Earlier-generation devices were bulkier and required a more involved surgical pocket, but the current generation of ILRs are slim enough that some are described as “injectable,” delivered through a tool that functions more like a large needle than a scalpel. This miniaturization has made the procedure simpler and better tolerated.
Complication Rates
Because the device sits just under the skin and has no wires running into the heart, complication rates are low compared with pacemakers or defibrillators. A real-world study from two Canadian centers found complications in about 3.3% of patients, mostly site infections and pain requiring device removal or pocket revision.
A larger analysis of adverse-event reports, however, paints a more detailed picture. Pain or discomfort was the most commonly reported issue, followed by site infection, skin erosion where the device pushes against the surface, and impaired healing. The LOOP study, which implanted over 1,400 devices, reported that less than 1% of patients experienced adverse events serious enough to require device removal, though patients who needed the device repositioned during the initial procedure had a noticeably higher rate of complications afterward. Infections were also more common when the procedure was done in a standard procedure room rather than an electrophysiology lab.
A study tracking patients who kept their devices well past the recommended replacement time found that the overall complication rate was about 8%, but complication risk was highest in the first six months and did not climb significantly even when devices were left in place for an average of five and a half years beyond the recommended window.
How Long the Battery Lasts
Current ILRs are designed to monitor for roughly three years, though real-world battery life varies. A large single-center registry found a median battery longevity of 42 months, with nearly all devices reaching their specified lifespan. However, the time to battery depletion varied by up to 33 months among the same device models, depending on how many recordings were triggered and how heavily the remote-monitoring features were used.
Once the battery runs out or the monitoring period is over, the device can be removed through another brief procedure. Some patients end up keeping inactive devices in place for years without issues, while others have them removed promptly. Whether to leave a depleted ILR in place or remove it is usually a shared decision between you and your doctor, informed by whether the device is causing discomfort or whether new monitoring is needed.
Why Doctors Recommend an ILR
The classic reason is unexplained fainting. When someone has had repeated episodes of syncope and standard tests like a Holter monitor, echocardiogram, and stress test have come back normal, an ILR gives doctors months or years of continuous data to catch whatever is happening. A Cochrane review comparing ILRs with conventional diagnostic workups found that ILRs provided significantly more diagnoses at long-term follow-up. A national database analysis in Germany found that among syncope patients with an ILR, the overall yield of cardiac arrhythmia diagnoses was 65% over two years, and about one in five patients went on to receive a pacemaker.
Cryptogenic Stroke
The other major indication is detecting atrial fibrillation after a stroke with no obvious cause. If a stroke is labeled “cryptogenic,” meaning its origin is unclear, the concern is that brief, undetected episodes of atrial fibrillation may have thrown a blood clot to the brain. Finding that atrial fibrillation matters because it changes treatment: patients with confirmed AF typically need blood thinners to prevent another stroke.
The landmark CRYSTAL AF trial showed that by 12 months, atrial fibrillation had been detected in about 12% of patients monitored with an ILR versus just 2% of patients in the conventional monitoring group. A multinational registry found even higher rates over longer follow-up, with AF detected in about 28% of cryptogenic stroke patients within three years of ILR insertion, with a median time to detection of roughly eight months. In a European cohort followed for three years, AF was found in over 40% of patients, and the vast majority of those who tested positive were started on blood thinners.
Inherited Heart Conditions
Guidelines have expanded the list of reasons to use an ILR beyond syncope and stroke. The 2018 European Society of Cardiology syncope guidelines added indications for patients with inherited cardiomyopathies, inherited channelopathies (conditions like Brugada syndrome and long QT syndrome), suspected but unproven epilepsy, and unexplained falls. In patients with hypertrophic cardiomyopathy who were considered low or intermediate risk for sudden death, an ILR detected significantly more arrhythmic events requiring intervention than conventional Holter monitoring over 30 months, though the two methods were similar at catching ventricular tachycardia specifically.
ILRs Versus Other Monitors
A standard Holter monitor records continuously for 24 to 48 hours. External loop recorders can be worn for a few weeks. Neither catches arrhythmias that happen infrequently. A randomized trial comparing external loop recorders with Holter monitors in patients with syncope or near-syncope found that loop recorders identified or excluded an arrhythmia in 63% of patients versus 24% for Holter monitors. But even external loop recorders have a limited wearing period and depend on patient compliance.
The ILR’s advantage is time. Because it monitors for years rather than days or weeks, it catches events that external monitors would miss entirely. In patients with peripartum cardiomyopathy, adding ILR monitoring to standard 24-hour Holter monitoring increased the detection of arrhythmic events from about 7% to 40%.
Consumer wearables, like smartwatches with ECG features, have entered the conversation as well. These devices can opportunistically detect AF, but they rely on the wearer initiating a recording or the watch happening to sample at the right moment. They are not continuously recording a full ECG strip. For someone who needs definitive, round-the-clock monitoring after a cryptogenic stroke or recurrent unexplained syncope, wearables are generally considered complementary rather than a replacement.
The False-Positive Problem
One of the biggest practical headaches with ILRs is false alarms. A systematic review found that false-positive alarms accounted for roughly 60% of all remote transmissions and affected about one in five monitored patients. False AF alerts were the most common culprit, usually triggered by premature heartbeats rather than true atrial fibrillation. Where the device was positioned mattered: implantation away from the standard parasternal site was the only identified predictor of more false alarms.
The accuracy of different ILR brands varies substantially. A multicenter comparison of the four currently used devices found wide differences in how reliably each one identified real arrhythmias. For AF detection, positive predictive values ranged from a high of 0.73 for one manufacturer down to just 0.23 for another, meaning that at the low end, fewer than one in four AF alerts was actually atrial fibrillation. For pause detection, the range was even more dramatic, from 0.70 at the top to just 0.01 at the bottom. Every brand produced a substantial burden of false positives despite algorithmic enhancements. These false alarms require staff time to review and can cause unnecessary patient worry.
How AI Algorithms Are Reducing Alert Burden
The latest generation of ILRs incorporates machine-learning algorithms designed to filter out false-positive signals before they reach the clinical team. Historically, about 75% of ILR alerts were false positives, creating a significant workload for the nurses and technicians responsible for reviewing transmissions. Newer devices with AI-based dual-stage algorithms and the ability to be reprogrammed remotely have shown higher true-positive rates in routine clinical use, reducing the volume of alerts that need human review without missing arrhythmias that would change treatment.
Remote reprogramming is a meaningful step forward. Rather than requiring an in-person visit to adjust device sensitivity settings, clinicians can now tweak the detection parameters over the air. If a particular patient is generating excessive false alarms due to frequent premature beats, the algorithm’s thresholds can be fine-tuned without the patient leaving home.
Does Finding Atrial Fibrillation Actually Prevent Strokes?
This is where the story gets more nuanced than you might expect. The intuition is straightforward: find AF, start blood thinners, prevent stroke. But the largest randomized trial testing this approach, the LOOP study, delivered a surprising result. Screening with ILRs tripled the rate of AF detection and led to roughly twice as many patients starting anticoagulation therapy compared with the control group. Yet there was no significant reduction in the risk of stroke or systemic arterial embolism in the ILR-screened group.
The study’s authors suggested that not all atrial fibrillation discovered through screening may warrant anticoagulation. Brief, low-burden episodes of AF detected by prolonged monitoring may not carry the same stroke risk as the sustained AF typically found when someone shows up with symptoms. This finding has complicated clinical decision-making: detecting AF is useful, but the threshold at which screen-detected AF should trigger blood-thinner therapy is still an open question.
In the specific context of cryptogenic stroke, however, the calculus is different. These patients have already had a stroke, so the threshold for starting anticoagulation after finding AF is much lower. In a cohort of cryptogenic stroke patients monitored for three years, over 40% had AF detected, and 84% of those patients were started on oral anticoagulation.
ILRs in Children and Adolescents
ILRs are not just for adults. Pediatric cardiologists use them in children and teenagers with unexplained syncope, palpitations, or known arrhythmia-prone conditions. A study of patients under 21 years old found that 37% had a clinically significant arrhythmia detected by ILR, and one in four had a resulting change in their clinical management, whether that meant starting medication, adjusting existing therapy, or proceeding to pacemaker or defibrillator implantation.
A larger pediatric cohort of 155 patients with a median age of about 11 years showed even stronger results. Diagnostic arrhythmias were recorded in 60% of symptom-triggered transmissions and 80% of automatic device-triggered recordings. Sinus pauses and ventricular tachycardia were the most commonly detected problems. Roughly 80% of children with ILR-diagnosed arrhythmias went on to receive targeted management. Minor complications occurred in only 2.5% of patients, and no serious adverse events were reported.
For families, an ILR can serve a dual purpose. Beyond its diagnostic function, it offers reassurance: knowing that every heartbeat is being monitored can reduce the anxiety that comes with having a child who faints without explanation.
What Patients Actually Experience
Living with an ILR involves little day-to-day inconvenience for most people. The device is small enough that it is barely visible under the skin, and after the insertion site heals, most patients forget it is there. A study tracking anxiety levels found that patients’ anxiety scores dropped by about half within six weeks of implantation and by 73% at twelve weeks, a statistically significant improvement. Women showed greater anxiety reduction than men at both time points.
That said, the experience is not universally positive. A scoping review of patient perspectives found that while some patients felt empowered and reassured by the monitoring, others experienced significant health-related anxiety, particularly around waiting for results or receiving alerts. The quality of the relationship with the medical team mattered: patients who felt well-informed and communicated with tended to cope better than those who felt left in the dark about what the device was finding.
MRI Compatibility
Because the ILR contains no leads running into the heart, MRI safety is generally less of a concern than it is with pacemakers or defibrillators. Studies have shown that MRI scanning can be performed in patients with an ILR without harm to the patient or permanent damage to the device. However, the magnetic field does produce artifact on the ILR’s recordings that can mimic abnormal rhythms like bradycardia or tachycardia. If you have an MRI while wearing an ILR, your clinical team needs to know so they can disregard any recordings from that time window and avoid mistakenly attributing symptoms to an arrhythmia that was actually just scanner interference.
Cost-Effectiveness
An ILR costs more up front than a conventional diagnostic workup involving Holter monitors, tilt-table tests, and electrophysiology studies. But because those conventional tests often fail to produce a diagnosis, patients frequently cycle through repeat testing, emergency department visits, and hospitalizations. When measured per diagnosis rather than per test, ILR monitoring tends to come out ahead. An economic analysis found that the cost-effectiveness of ILR compared with no further testing was under £20,000 per quality-adjusted life year for both unexplained syncope and suspected arrhythmic syncope, well within the threshold most health systems consider acceptable.
Early deployment of an ILR can also shorten the diagnostic journey, which has downstream economic benefits: fewer repeat clinic visits, fewer ambulance calls for undiagnosed fainting episodes, and faster initiation of definitive treatment when an arrhythmia is found.
How the Devices Have Evolved
The first ILRs, introduced in the late 1990s, were large enough that implantation required a meaningful surgical pocket and left a noticeable bump under the skin. Each successive generation has been smaller, with better battery life and more sophisticated detection algorithms. Current devices weigh just a few grams and are thin enough to be inserted through a small incision using a dedicated tool, earning the term “insertable cardiac monitor” in clinical parlance. Remote monitoring, AI-enhanced algorithms, and remote reprogramming are all features that did not exist a decade ago. The shift has been toward making the device less of an event in the patient’s life: easier to place, harder to notice, smarter about what it flags, and more transparent in how it communicates with the care team.
Four manufacturers currently produce ILRs, each with different algorithmic approaches and hardware designs. As the multicenter accuracy comparison made clear, these are not interchangeable products. The choice of device can meaningfully affect the volume of false alerts, the types of arrhythmias detected most reliably, and the clinical workflow for the monitoring team. For patients, this is worth a conversation with your cardiologist: the brand of ILR matters, not just whether you get one.